190 related articles for article (PubMed ID: 30096339)
1. Alkyl-imino sugars inhibit the pro-oncogenic ion channel function of human papillomavirus (HPV) E5.
Wetherill LF; Wasson CW; Swinscoe G; Kealy D; Foster R; Griffin S; Macdonald A
Antiviral Res; 2018 Oct; 158():113-121. PubMed ID: 30096339
[TBL] [Abstract][Full Text] [Related]
2. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
3. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes.
Straight SW; Hinkle PM; Jewers RJ; McCance DJ
J Virol; 1993 Aug; 67(8):4521-32. PubMed ID: 8392596
[TBL] [Abstract][Full Text] [Related]
4. Impact of HPV E5 on viral life cycle via EGFR signaling.
Ilahi NE; Bhatti A
Microb Pathog; 2020 Feb; 139():103923. PubMed ID: 31836496
[TBL] [Abstract][Full Text] [Related]
5. Animal models of papillomavirus pathogenesis.
Campo MS
Virus Res; 2002 Nov; 89(2):249-61. PubMed ID: 12445664
[TBL] [Abstract][Full Text] [Related]
6. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
[TBL] [Abstract][Full Text] [Related]
7. High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors.
Wetherill LF; Holmes KK; Verow M; Müller M; Howell G; Harris M; Fishwick C; Stonehouse N; Foster R; Blair GE; Griffin S; Macdonald A
J Virol; 2012 May; 86(9):5341-51. PubMed ID: 22357280
[TBL] [Abstract][Full Text] [Related]
8. Human Papillomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance.
Scott ML; Woodby BL; Ulicny J; Raikhy G; Orr AW; Songock WK; Bodily JM
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666385
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation.
Fehrmann F; Klumpp DJ; Laimins LA
J Virol; 2003 Mar; 77(5):2819-31. PubMed ID: 12584305
[TBL] [Abstract][Full Text] [Related]
10. Two conserved amino acids differentiate the biology of high-risk and low-risk HPV E5 proteins.
Sudarshan SR; Schlegel R; Liu X
J Med Virol; 2022 Sep; 94(9):4565-4575. PubMed ID: 35509176
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus type 11 and 16 E5 represses p21(WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes.
Tsao YP; Li LY; Tsai TC; Chen SL
J Virol; 1996 Nov; 70(11):7535-9. PubMed ID: 8892872
[TBL] [Abstract][Full Text] [Related]
12. E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis.
Zhang B; Spandau DF; Roman A
J Virol; 2002 Jan; 76(1):220-31. PubMed ID: 11739687
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus E5 oncoproteins bind the A4 endoplasmic reticulum protein to regulate proliferative ability upon differentiation.
Kotnik Halavaty K; Regan J; Mehta K; Laimins L
Virology; 2014 Mar; 452-453():223-30. PubMed ID: 24606699
[TBL] [Abstract][Full Text] [Related]
14. Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer.
Um SH; Mundi N; Yoo J; Palma DA; Fung K; MacNeil D; Wehrli B; Mymryk JS; Barrett JW; Nichols AC
J Clin Virol; 2014 Sep; 61(1):94-100. PubMed ID: 25027574
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of MHC class I is a property common to papillomavirus E5 proteins.
Ashrafi GH; Brown DR; Fife KH; Campo MS
Virus Res; 2006 Sep; 120(1-2):208-11. PubMed ID: 16780984
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus type 18 E5 oncogene supports cell cycle progression and impairs epithelial differentiation by modulating growth factor receptor signalling during the virus life cycle.
Wasson CW; Morgan EL; Müller M; Ross RL; Hartley M; Roberts S; Macdonald A
Oncotarget; 2017 Nov; 8(61):103581-103600. PubMed ID: 29262586
[TBL] [Abstract][Full Text] [Related]
17. Effect of human papillomavirus type 16 oncogenes on MAP kinase activity.
Gu Z; Matlashewski G
J Virol; 1995 Dec; 69(12):8051-6. PubMed ID: 7494320
[TBL] [Abstract][Full Text] [Related]
18. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle.
Genther SM; Sterling S; Duensing S; Münger K; Sattler C; Lambert PF
J Virol; 2003 Mar; 77(5):2832-42. PubMed ID: 12584306
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus type 16 E5 protein as a therapeutic target.
Kim SW; Yang JS
Yonsei Med J; 2006 Feb; 47(1):1-14. PubMed ID: 16502480
[TBL] [Abstract][Full Text] [Related]
20. Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2.
Toft-Bertelsen TL; Jeppesen MG; Tzortzini E; Xue K; Giller K; Becker S; Mujezinovic A; Bentzen BH; B Andreas L; Kolocouris A; Kledal TN; Rosenkilde MM
Commun Biol; 2021 Dec; 4(1):1347. PubMed ID: 34853399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
